Based on the information provided, it is possible for co-administered medications to impact the duration of Cosentyx (secukinumab) treatment. Secukinumab is a biologic medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2].

According to the COVID-19 Treatment Guidelines from the National Institutes of Health, co-administration of Cosentyx with certain antiviral medications, such as ritonavir-boosted nirmatrelvir (Paxlovid), may result in decreased serum concentrations of secukinumab [3]. This interaction could potentially reduce the efficacy of Cosentyx, leading to a need for more frequent dosing or a change in treatment duration.

However, it is important to note that the information provided does not cover all possible drug-drug interactions for Cosentyx. Therefore, it is crucial for healthcare providers to carefully review a patient's medication regimen and consult reliable resources or pharmacists when necessary to ensure safe and effective treatment [3].

In summary, co-administered medications can impact the duration of Cosentyx treatment, as some drugs may affect the serum concentrations of secukinumab. Healthcare providers should be aware of potential drug-drug interactions and consult appropriate resources to ensure safe and effective treatment.

Sources:

1. [DrugPatentWatch](https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX)
2. [Cosentyx.com](https://www.cosentyx.com/)
3. [NIH COVID-19 Treatment Guidelines](https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/)